Cargando…

Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein kinase

T-cell-originated protein kinase (TOPK) is highly and frequently expressed in various cancer tissues and plays an indispensable role in the mitosis of cancer cells, and therefore, it is an important target for drug treatment of tumor. Ilaprazole was identified to be a potent TOPK inhibitor. The data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Mengzhu, Luan, Shanshan, Gao, Suyu, Cheng, Li, Hao, Bin, Li, Jiacheng, Chen, Yao, Hou, Xuemei, Chen, Lixia, Li, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503601/ https://www.ncbi.nlm.nih.gov/pubmed/28388576 http://dx.doi.org/10.18632/oncotarget.16609

Ejemplares similares

Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase
por: Zeng, Xiaoyu, et al.
Publicado: (2016)

Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori
por: Niu, Min, et al.
Publicado: (2022)

Accelerating Development of Benziamidazole-Class Proton Pump Inhibitors: A Mechanism-Based PK/PD Model to Optimize Study Design with Ilaprazole as a Case Drug
por: Jia, Ranran, et al.
Publicado: (2021)

A natural inhibitor of kidney-type glutaminase: a withanolide from Physalis pubescens with potent anti-tumor activity
por: Wu, Canrong, et al.
Publicado: (2017)

Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1
por: Zheng, Mengzhu, et al.
Publicado: (2017)

Ilaprazole and Clopidogrel Resistance in Acute Stroke Patients
por: Lim, In Hwan, et al.
Publicado: (2022)

Effects of ilaprazole on the steady-state pharmacodynamics of clopidogrel in healthy volunteers: An open-label randomized crossover study
por: Ye, Zekang, et al.
Publicado: (2022)

Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2
por: Li, Wei, et al.
Publicado: (2017)

Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options
por: van Leeuwen, Roelof W. F., et al.
Publicado: (2017)

The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori
por: Lee, Seung Woo, et al.
Publicado: (2020)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Prospective Single Arm Study on the Effect of Ilaprazole in Patients with Heartburn but No Reflux Esophagitis
por: Song, In Ji, et al.
Publicado: (2018)

Improved motility in the gastrointestinal tract of a postoperative ileus rat model with ilaprazole
por: Kim, Geon Min, et al.
Publicado: (2021)

The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori: Erratum
Publicado: (2021)

Use of proton pump inhibitors for the risk of gastric cancer
por: Gao, Huiqin, et al.
Publicado: (2022)

Proton Pump Inhibitors and Gastritis
por: Suzuki, Masayuki, et al.
Publicado: (2008)

Proton pump inhibitors and gastroenteritis
por: Hassing, Robert-Jan, et al.
Publicado: (2016)

Deprescribing proton pump inhibitors
por: Teh, Kim Jun Kevin, et al.
Publicado: (2023)

High Dose Ilaprazole/Amoxicillin as First-Line Regimen for Helicobacter pylori Infection in Korea
por: Kwack, WonGun, et al.
Publicado: (2016)

Identification of the New In Vivo Metabolites of Ilaprazole in Rat Plasma after Oral Administration by LC-MS: In Silico Prediction of the H(+)/K(+)-ATPase Inhibitor
por: Zhang, Guiqiu, et al.
Publicado: (2021)

Proton-Pump Inhibitors Suppress T Cell Response by Shifting Intracellular Zinc Distribution
por: Liu, Wenlei, et al.
Publicado: (2023)

Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19
por: Zhang, Xiao-Yu, et al.
Publicado: (2021)

Proton pump inhibitors affect sperm parameters by regulating aquaporins
por: Ding, Fadian, et al.
Publicado: (2023)

Proton pump inhibitors and the risk of hospital-acquired acute kidney injury in children
por: Li, Yanqin, et al.
Publicado: (2020)

Esophageal Acidification During Nocturnal Acid-breakthrough with Ilaprazole Versus Omeprazole in Gastroesophageal Reflux Disease
por: Karyampudi, Arun, et al.
Publicado: (2017)

The Association of Diuretics and Proton Pump Inhibitors With Chondrocalcinosis
por: Felson, David T., et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)

Proton pump inhibitors and hypomagnesemia monitoring
por: Lemon, Thomas I
Publicado: (2013)

Use and overuse of proton pump inhibitors
por: Staiano, Annamaria, et al.
Publicado: (2015)

Symptomatic hypomagnesemia and proton pump inhibitors
por: Tin, Sim Sai, et al.
Publicado: (2014)

The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
por: Buti, Sebastiano, et al.
Publicado: (2022)

Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness
por: Brett, Stephen
Publicado: (2005)

Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis
por: Ghebremariam, Yohannes T, et al.
Publicado: (2015)

Stretta procedure versus proton pump inhibitors for the treatment of nonerosive reflux disease: A 6-month follow-up
por: He, Suyu, et al.
Publicado: (2020)

Selective Targeting of Virus Replication by Proton Pump Inhibitors
por: Watanabe, Susan M., et al.
Publicado: (2020)

Proton pump inhibitors display anti‐tumour potential in glioma
por: Li, Bihan, et al.
Publicado: (2022)

Risk of Pyogenic Liver Abscess in Proton Pump Inhibitor Users: New Inventory of Proton Pump Inhibitor Induced Complications?
por: Bang, Ki Bae
Publicado: (2021)

Management of laryngopharyngeal reflux with proton pump inhibitors
por: Reimer, Christina, et al.
Publicado: (2008)

Proton Pump Inhibitor Induced Depigmentation in Vitiligo
por: Holla, Anantha Prasad, et al.
Publicado: (2011)

Proton pump inhibitor-induced hypomagnesemic hypoparathyroidism
por: Swaminathan, Krishnan
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6smjvs50p1mq45mpsr26riu61v